JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Visser, Adele
|
|
| dc.contributor.author | Hoosen, Anwar Ahmed
|
|
| dc.date.accessioned | 2012-12-12T11:33:05Z | |
| dc.date.available | 2012-12-12T11:33:05Z | |
| dc.date.issued | 2012-01 | |
| dc.description.abstract | Human papillomavirus (HPV) infection has been estimated to cause 270 000 deaths worldwide annually from cervical cancer and approximately 80% of these occur in resource-poor countries.1 In South Africa, cervical cancer is the second most common malignancy among women, with the highest rate among black women aged 66 - 69 years.2 With the development of prophylactic HPV vaccines there are prospects of significant reduction in morbidity and mortality due to HPV infection and its complications. | en_US |
| dc.description.uri | http://www.cmej.org.za/index.php/cmej | en_US |
| dc.identifier.citation | Visser, A & Hoosen, A 2012, 'Human papillomavirus (HPV) vaccines', CME : Continuing Medical Education, vol. 30, no. 1, pp. 29. | en_US |
| dc.identifier.issn | 1016-6742 (print) | |
| dc.identifier.issn | 2078-5143 (online) | |
| dc.identifier.uri | http://hdl.handle.net/2263/20794 | |
| dc.language.iso | en | en_US |
| dc.publisher | Health and Medical Publishing Group | en_US |
| dc.rights | Health and Medical Publishing Group | en_US |
| dc.subject | Human papillomavirus (HPV) vaccines | en_US |
| dc.title | Human papillomavirus (HPV) vaccines | en_US |
| dc.type | Article | en_US |
